Certara's Better Drug Discovery and Development Process
The drug discovery and development process is long and expensive with more failures than successes. At Certara, we anticipate and address your critical drug discovery and development risks and decisions using biosimulation and tech-enabled services.
In 2021, more than 2,000 customers worldwide chose Certara as their trusted partner for our gold-standard biosimulation software and tech-enabled services. We support confident decision-making throughout the entire biopharma R&D process to reduce cycle times, lower costs and improve outcomes for patients.
Additionally, 17 global regulatory agencies have adopted our Phoenix™ PK/PD and/or Simcyp™ PBPK Simulator software platforms, including the US FDA, Japan's PMDA and China's NMPA.
We are proud to say that our customers, who use our biosimulation software and services, have received 90% of all new drug approvals by the FDA since 2014.
How we help our clients
Latest from Certara
Webinar: Feb 16
PBPK Modeling of Antibody-Drug Conjugates
Scaling to support a BLA that grew 8x larger than originally planned
Family Driven Development of Treatments for Rare Pediatric Neurological Diseases
Organizing Complex Virology Datasets into FDA-Ready Format using SAS Programming
How to Succeed in a Transformational Med Tech Landscape: Regulatory, Evidence, and Communication Strategies Symposium
Article: Drug Discovery World
The value of scientific intelligence in drug discovery
Application of quantitative systems pharmacology to guide the optimal dosing of COVID-19 vaccines
What Oncology Drug Developers Should Expect from the FDA’s Project Optimus
The Essential Components of a Credible Biomarker Strategy Plan for Your Drug Development Candidate
Article: BioIT World
New Discovery Data Architecture Needed to Support New Modalities